title: Discovery of less nephrotoxic FK506 analogs and determining immunophilin dependence of immunosuppressant nephrotoxicity with a novel single-dose rat cisplatin potentiation assay.
abstract: Comparing nephrotoxicity of numerous drug analogs is impractical with chronic in vivo models. We devised a new cisplatin potentiation assay (CISPA) that sensitively detects renal injury as a serum creatinine increase when only one dose of test compound is followed by cisplatin. Reference nephrotoxins known to act on various sites in kidney tubules, glomeruli or renal papilla were all detected by the CISPA at single doses that without cisplatin gave little change, which showed that this simple, sensitive assay has broad potential utility for mechanistic studies of nephrotoxicity. We used the CISPA both to probe the nephrotoxic mode of action of immunosuppressants and to search for safer compounds. Although several non-nephrotoxic immunosuppressants were inactive, cyclosporine, FK506, ascomycin (C21-ethyl-FK506) and rapamycin were nephrotoxic in the CISPA at single doses equal to the daily amounts required to reduce creatinine clearance with 14 days of treatment. Similar therapeutic indices were derived comparing toxicity by either method to prevention of rat ear-heart allograft rejection. C18-OH-ascomycin, an FK506-binding protein (FKBP) antagonist, reversed in vivo immunosuppression by FK506 and ascomycin in the rat, and pretreatment in the CISPA blocked FK506 and ascomycin nephrotoxicity, which showed a common immunophilin dependence. Rapamycin nephrotoxicity was unaffected (as with cyclosporine), which indicated that binding to FKBP was not required. Rapamycin nephrotoxicity thus appears mechanistically unrelated to its immunosuppressive mode of action. Screening with the CISPA enabled discovery of A-119435, a less nephrotoxic ascomycin analog having a 10-fold higher therapeutic index.
authors.affiliation: Immunologic Diseases Area, Abbott Laboratories, Abbott Park, Illinois 60064-3500, USA.
authors.forename: K W
authors.initials: KW
authors.lastname: Mollison
authors.forename: T A
authors.initials: TA
authors.lastname: Fey
authors.forename: R A
authors.initials: RA
authors.lastname: Krause
authors.forename: J M
authors.initials: JM
authors.lastname: Andrews
authors.forename: P T
authors.initials: PT
authors.lastname: Bretheim
authors.forename: J A
authors.initials: JA
authors.lastname: Brandt
authors.forename: M
authors.initials: M
authors.lastname: Kawai
authors.forename: R
authors.initials: R
authors.lastname: Wagner
authors.forename: G C
authors.initials: GC
authors.lastname: Hsieh
authors.forename: J R
authors.initials: JR
authors.lastname: Luly
mesh_terms: D000818:Animals; D002352:Carrier Proteins / Q000378:metabolism*; D002945:Cisplatin / Q000633:toxicity*; D004268:DNA-Binding Proteins / Q000378:metabolism*; D004347:Drug Interactions; D006360:Heat-Shock Proteins / Q000378:metabolism*; D007166:Immunosuppressive Agents / Q000633:toxicity*; D007668:Kidney / Q000187:drug effects*; D008297:Male; D051381:Rats; D011914:Rats, Inbred BN; D011916:Rats, Inbred F344; D011917:Rats, Inbred Lew; D017207:Rats, Sprague-Dawley; D016559:Tacrolimus / Q000031:analogs & derivatives* / Q000633:toxicity; D022021:Tacrolimus Binding Proteins
chemical_list: D002352:Carrier Proteins; D004268:DNA-Binding Proteins; D006360:Heat-Shock Proteins; D007166:Immunosuppressive Agents; C058028:immunomycin; D022021:Tacrolimus Binding Proteins; D002945:Cisplatin; D016559:Tacrolimus